Abivax Reacquires Royalty Certificates and Proceeds with $45M ADS Offering

Abivax has announced the reacquisition of its royalty certificates originally issued in September 2022. This move reduces financial overhang and is paired with a $45 million offering of American Depositary Shares (ADS), priced at $111.57 per ADS, based on recent trading averages. The offering supports the company's long-term commercialization and shareholder value enhancement.

The share issuance will lead to a dilution of approximately 0.5% in the company's capital. The cash position projected for Q4 2027 remains stable, indicating no immediate change post repurchase. The transaction is expected to close around May 7, 2026.

This strategy reflects Abivax's aim to streamline its financial obligations while preparing for future commercialization, focusing on treatments for chronic inflammatory diseases. Investors should be aware of potential risks, including market price impacts and future capital needs.